B12 deficiency

Vitamin B12 is a critical water-soluble vitamin, essential for normal neurological function and haematopoiesis. Despite the widespread availability of nutritious food, vitamin B12 deficiency remains relatively common due to its complex absorption pathway and various contributing clinical factors.

Biological Role of Vitamin B12

Vitamin B12 serves as a cofactor for two key enzymes:

Methionine synthase – required for DNA synthesis and methylation.
Methylmalonyl-CoA mutase – involved in fatty acid and amino acid metabolism.

Deficiency impairs these pathways, leading to:

Impaired DNA synthesis → megaloblastic anaemia
Neurological dysfunction → peripheral neuropathy, cognitive decline
Systemic effects on multiple organ systems

Neurologic Function:
- Peripheral Neuropathy: Vitamin B12 deficiency can lead to nerve damage, causing symptoms like tingling, numbness, and burning sensations in the hands and feet.
- Cognitive Impairment: Deficiency can result in memory loss, confusion, and cognitive decline.
- Gait Impairment: Patients may experience balance problems and difficulty walking.
Red Blood Cell Production:
- Macrocytic Anemia: B12 deficiency causes the production of abnormally large and immature red blood cells.
- Pancytopenia: This condition can also lead to a decrease in all types of blood cells, including white blood cells and platelets.
DNA Synthesis:
- B12-dependent Reactions:
  - Methylmalonyl-CoA → Succinyl-CoA: B12 is essential for converting methylmalonic acid to succinyl-CoA, a critical component of the Krebs cycle.
  - Homocysteine → Methionine: B12 helps convert homocysteine to methionine, which is vital for angiogenesis and other cellular functions.
  - 5-Methyltetrahydrofolate to Tetrahydrofolate: This conversion is crucial for DNA synthesis and red blood cell production.

Absorption, Transport, and Clinical Implications

B12 absorption requires:

Gastric acid → intrinsic factor → terminal ileum

After absorption:

Transcobalamin → active B12 (holotranscobalamin) → delivered to cells
Haptocorrin → inactive circulating pool

Only holotranscobalamin reflects usable B12 Deficiency may exist despite “normal” total B1

1. Absorption Mechanism (Multi-Step Process)

A. Gastric Phase

Dietary B12 is protein-bound
Released in the stomach via:
- Pepsin + hydrochloric acid (HCl)
Binds to haptocorrin (R-protein) from salivary and gastric glands

👉 Clinical relevance:

Impaired by:
- PPIs / H2 blockers
- Atrophic gastritis

B. Duodenal Phase

Pancreatic proteases degrade haptocorrin
Free B12 binds to intrinsic factor (IF)
(produced by gastric parietal cells)

C. Ileal Absorption

B12–IF complex absorbed in the terminal ileum
Via cubilin receptor-mediated endocytosis

👉 This is the primary physiological absorption pathway

2. Entry into Circulation & Transport (Key Concept)

Once absorbed, B12 enters the bloodstream and binds to two transport proteins:

A. Transcobalamin II (TCII)

Binds ~20% of circulating B12
Forms:

✅ Holotranscobalamin (holoTC) = B12 + transcobalamin

👉 This is the biologically active fraction

Delivered to cells via CD320 receptor-mediated endocytosis

B. Haptocorrin

Binds ~80% of circulating B12
Forms holohaptocorrin

👉 This is:

Biologically inactive
Not available for cellular uptake
Acts as a circulating storage/binding pool

Key Clinical Principle: Only holotranscobalamin is taken up by cells and reflects bioavailable B12.

3. Alternate Absorption Pathway

~1% absorbed via passive diffusion
Independent of intrinsic factor and ileum

👉 Basis for high-dose oral B12 therapy

4. Intracellular Activation

After cellular uptake, B12 is converted into active coenzyme forms:

Form	Location	Function
Methylcobalamin	Cytosol	Homocysteine → Methionine
Adenosylcobalamin	Mitochondria	Methylmalonyl-CoA → Succinyl-CoA

5. Storage

Stored primarily in the liver (2–5 mg)
Stores last 3–5 years
Explains delayed onset of deficiency

Clinical Manifestations of Vitamin B12 Deficiency

Haematological

Megaloblastic anaemia: Macrocytic anaemia with hypersegmented neutrophils
Pancytopenia in severe cases
Pernicious anaemia: An autoimmune cause of B12 deficiency with gastric atrophy

Neurological

Paresthesias, numbness, burning sensations
Peripheral neuropathy
Subacute combined degeneration:
- Involves posterior columns and corticospinal tracts
- Proprioceptive loss, ataxia, hyporeflexia, spasticity, incontinence

Neuropsychiatric

Depression
Cognitive impairment, dementia
Personality change, psychosis
Potential association with Alzheimer’s disease in observational studies

Cardiovascular

Elevated homocysteine levels may increase risk of atherothrombosis, MI, and stroke (though causality remains debated)

Maternal and Infant Outcomes

Maternal B12 deficiency:
- Neural tube defects
- Intrauterine growth restriction
- Developmental delay, failure to thrive, hypotonia, ataxia in infants

Pernicious Anaemia

Feature	Description
Cause	Autoimmune destruction of parietal cells → ↓IF
Autoantibodies	Anti-intrinsic factor anti-parietal cell
Associations	T1DM Hashimoto’s Vitiligo Autoimmune gastritis Addison disease
Epidemiology	Common in elderly (>60 years)
Onset	Gradual over 2–5 years Often starts in early–mid adulthood (20s–40s) but is silent Clinical pernicious anaemia – Peak incidence 60–80 years; uncommon <40 y
Features	Megaloblastic anaemia neurological symptoms glossitis

Differential Diagnosis of Vitamin B12 Deficiency

1. Impaired Intrinsic Factor (IF) Production

Atrophic gastritis
- Age-related mucosal atrophy
- Helicobacter pylori infection
- Associated with type 1 diabetes
- More common in the elderly
Pernicious anaemia
- Autoimmune destruction of gastric parietal cells
- Anti-intrinsic factor and anti-parietal cell antibodies
- Progression:
  - Asymptomatic gastritis → appears up to 30 years prior
  - Iron deficiency → precedes B12 deficiency by ~20 years
Post-gastrectomy states
- Roux-en-Y gastric bypass
- Total or subtotal gastrectomy
- (deficiency may appear within 12–24 months because parietal cells are surgically bypassed or removed.)

2. Impaired Ileal Absorption

Inflammatory or structural disease
- Crohn’s disease
- Ileal resection
Infectious or infiltrative conditions
- Whipple’s disease
- Fish tapeworm (Diphyllobothrium latum) infestation
Other causes
- Zollinger–Ellison syndrome (gastrinoma) – acid inactivation of pancreatic enzymes impairs B12 release from haptocorrin

3. Medication-Induced Malabsorption

Metformin – impairs B12–IF complex uptake in the terminal ileum
Proton pump inhibitors (PPIs) – reduce gastric acid, impairing B12 release from food
H2 receptor antagonists – similar effect to PPIs

4. Genetic and Other Malabsorptive Causes

Coeliac disease – mucosal damage to terminal ileum
Congenital transcobalamin II deficiency – rare autosomal recessive disorder causing functional B12 deficiency

5. Inadequate Dietary Intake

Vegan diets – B12 is absent from non-animal sources
Elderly adults (>75 years) – reduced intake and hypochlorhydria, gastric atrophy
Chronic alcoholism – poor intake and mucosal damage
Psychiatric illness – dietary neglect
Exclusively breastfed infants of vegan mothers – limited B12 supply from maternal milk

When to order B12 studies

Clinical features

Megaloblastic or macrocytic anaemia, pancytopenia
Peripheral neuropathy, dorsal-column signs, cognitive decline, dementia
Unexplained fatigue, glossitis, infertility, depression

Conditions with high prevalence

Malabsorption: coeliac disease, IBD, pancreatic insufficiency, post-bariatric surgery
Dietary restriction: vegan/vegetarian diets, severe malnutrition, alcoholism
Medications: metformin, PPIs, H2-blockers, nitrous-oxide exposure, colchicine
Age > 65 y

Ix:

FBC
There is no single gold standard for diagnosing vitamin B12 deficiency.
A combination of tests is often required, particularly when clinical suspicion is high despite normal serum B12.

1. Serum B12 Testing

a. Total Vitamin B12

Measures active + inactive B12
Common screening test but has limited sensitivity/specificity due to high proportion of inactive haptocorrin-bound B12.
Reference intervals:
- Normal: >250 pmol/L
- Borderline: 150–250 pmol/L
- Deficient: <150 pmol/L

b. Holotranscobalamin (holoTC) (Active B12)

Reflects bioavailable B12
Only ~20% of circulating B12 is holoTC
This is the fraction delivered to tissues
Better correlates with tissue B12 status.
Drops before total B12 – Detects early / functional deficiency
Reference intervals:
- Normal: >35 pmol/L
- Borderline: 30–35 pmol/L
- Deficient: <30 pmol/L

2. Functional Markers

Deficient B12 activity leads to accumulation of precursor metabolites:

a. Homocysteine

Elevated in:
- B12 deficiency
- Folate deficiency
- B6 deficiency
- CKD, hypothyroidism, alcohol use
Sensitive but non-specific to B12 deficiency.

b. Methylmalonic Acid (MMA)

Most specific marker for B12 deficiency
Elevated in:
- B12 deficiency
- Renal impairment (false elevation)
Not always required if diagnosis already clear
May be normal in early deficiency

3. Autoantibody Testing

Indicated in suspected autoimmune aetiology of B12 deficiency:

Anti-parietal cell antibodies – High specificity -diagnostic of pernicious anaemia
Anti-intrinsic factor antibodies – Sensitive but non-specific, A negative anti-IF does not exclude pernicious anaemia

Suggestive of pernicious anaemia if positive.

Test	What it measures	Reference range†	Strengths / limitations
Total serum B12	Holo-TC + holo-haptocorrin	Deficient: <150 pmol/L Borderline: 150–250 pmol/L Adequate: >250 pmol/L	Widely available Symptoms can occur even in “normal” range (200–300)” – insensitive in early deficiency Elevated in liver/haemato-oncology states.
Holotranscobalamin (Active B12)	Bio-available fraction only	> 35 pmol/L (deficient < 30; borderline 30–35)	Better correlation with tissue stores; Medicare-rebate when total B12 low/borderline (automatically reflexed by many labs).
Methylmalonic acid (MMA)	Functional marker (mitochondrial pathway)	Age- & lab-specific (typically < 0.40 µmol/L)	↑ with B12 deficiency; falsely ↑ in renal impairment, inherited metabolic disorders; out-of-pocket cost.
Total homocysteine	Functional marker (cytosolic pathway)	< 15 µmol/L (fasting)	↑ with – B12, folate, B6 deficiency – hypothyroidism – renal impairment non-specific.
Anti-intrinsic factor Ab	Autoimmune pernicious anaemia	Positive/negative	High specificity low sensitivity (~50 %). Positive = diagnostic of pernicious anaemia (high specificity) Negative = does NOT exclude pernicious anaemia
Anti-parietal cell Ab	Autoimmune gastritis	Positive/negative	High sensitivity low specificity (false-positives in 7–10 % of healthy adults).

Interpretation

Normal total B12 + normal active B12
→ Deficiency unlikely
Low active B12 (± normal total B12)
→ Suggests early or functional deficiency
Total B12 <150 pmol/L OR active B12 <30 pmol/L
→ Deficiency very likely → treat and investigate cause
Borderline zone (Total 150–250 or Active 30–35)
→ Check MMA ± homocysteine
→ If elevated → treat
→ If normal but suspicion persists → consider therapeutic trial
Normal labs but strong clinical suspicion
→ Treat empirically
→ Neurological features may precede biochemical abnormalities

Medicare – B12 testing in Australia.

First-line test:
- order total B12 and/or active B12 (holotranscobalamin) under MBS item 66838.
- This has been allowed since 1 July 2025.
- Active B12 = bioavailable B12.
  - It can be useful when total B12 is harder to interpret, such as in some high-risk settings.
If the first test is abnormal or inconclusive, you can request
- MMA or homocysteine under item 66839
- in the same patient episode.
  - MMA is the more specific functional marker for B12 deficiency.
  - Homocysteine can be raised in B12 deficiency
    - but also in
      - folate deficiency
      - B6 deficiency
      - renal impairment
      - hypothyroidism
Routine repeat testing is limited:
- 66838 and 66839 are generally not billable more than once in 11 months.
If you need repeat testing earlier than 11 months
- USE item 66842 if there is defined clinical need.
  - 66842 can cover one or more of:
    - total B12
    - active B12
    - MMA
    - homocysteine.
  - Examples where 66842 may apply:
    - still symptomatic 3–6 months after prior testing
    - previous results were inconclusive
    - monitoring treatment
    - vegan/low B12 diet
    - metformin or PPI use
    - GI surgery
    - recent nitrous oxide use
    - other conditions associated with B12 deficiency risk.
On the pathology form, write the clinical reason clearly, for example:
- fatigue with macrocytosis
- peripheral neuropathy
- metformin use
- vegan diet
- monitoring treated B12 deficiency. This helps the lab apply the correct MBS item.

Easy rule:

66838 = first test
66839 = follow-up functional test if first test unclear/abnormal
66842 = earlier repeat or high-risk/ongoing clinical need.

Scenario	What to order	MBS item	Key rule
First test for suspected B12 deficiency	Total B12 and/or active B12 (holotranscobalamin)	66838	First-line testing from 1 July 2025
Initial result abnormal or inconclusive	MMA or homocysteine	66839	Must be billed in the same patient episode as 66838
Routine repeat testing	Repeat 66838 or 66839	66838 / 66839	Generally not more than once in 11 months
Need repeat testing earlier than 11 months	One or more of total B12, active B12, MMA, homocysteine	66842	Allowed when there is defined clinical need

When to use 66842	Examples
Persistent symptoms	Still symptomatic 3–6 months after 66838 or 66839
Inconclusive follow-up	66839 result inconclusive
Risk factors	Low B12 diet family history of B12 deficiency/autoimmune condition prior abdominal or pelvic radiotherapy prior GI surgery recent recreational nitrous oxide use monitoring B12 treatment B12-antagonistic medicines

Practical pathology form wording	Example
Suspected deficiency	“Fatigue / macrocytosis / neuropathy – assess B12 deficiency”
Medication risk	“Metformin/PPI use – assess B12 deficiency”
Diet risk	“Vegan / low B12 diet”
Monitoring	“Monitoring treated B12 deficiency”

Simple takeaway

Item	Meaning
66838	First-line total B12 and/or active B12
66839	MMA or homocysteine if first result is abnormal/inconclusive
66842	Earlier repeat / high-risk / ongoing clinical need

Management

Treat confirmed B12 deficiency and investigate the cause.

Correct folate and iron deficiency concurrently, but do not give folate alone if B12 deficiency is possible.

Dietary deficiency: oral cyanocobalamin 1 mg daily.

Pernicious anaemia / irreversible malabsorption: hydroxocobalamin 1000 mcg IM alternate days for 1–2 weeks, then weekly for 4–8 weeks, then every 3 months lifelong.

Neurological involvement: hydroxocobalamin 1000 mcg IM alternate days until no further improvement, then every 3 months lifelong.

Typical routine IM dose per injection = 1 mg

Situation	Preferred treatment	Dose / regimen	Duration / follow-up	Notes
Dietary B12 deficiency	Oral cyanocobalamin	1 mg PO daily	Review after 2–3 months; repeat B12/FBC, and consider MMA or homocysteine after 3–6 months if needed	High-dose oral is preferred when absorption is intact.
Drug-related deficiency (for example metformin, PPI)	Oral cyanocobalamin or IM if severe	1 mg PO daily	Reassess after the offending drug is stopped and deficiency corrected	Oral treatment is reasonable if absorption is otherwise adequate.
Pernicious anaemia / irreversible malabsorption / total gastrectomy / terminal ileum resection	IM hydroxocobalamin	1000 mcg IM on alternate days for 1–2 weeks, then weekly for 4–8 weeks, then every 3 months lifelong	Lifelong in irreversible causes	Standard Australian Prescriber regimen.
Severe symptomatic deficiency or neurological involvement	IM hydroxocobalamin	1000 mcg IM on alternate days until no further improvement, often at least 2–3 weeks	Then every 3 months lifelong if irreversible cause	Do not delay treatment if neurology is present.
Potentially reversible malabsorption	IM hydroxocobalamin initially	Same loading regimen as above	Then either every 3 months or switch to oral cyanocobalamin at least 1 mg daily once corrected	Depends on response and cause.
Nitrous oxide–related functional B12 deficiency	IM B12 preferred	RACGP: 1 mg IM on alternate days for 2 weeks. Some hospital protocols use 1 mg daily for 2 weeks then weekly/monthly until plateau	Continue longer if neurological improvement continues	Protocols vary; RACGP supports alternate-day dosing.
Asymptomatic low/borderline B12 with no anaemia or neurology	Usually oral cyanocobalamin if persistent	Often 1 mg PO daily	Repeat B12/FBC in 2–3 months	Investigate cause and escalate if poor biochemical response.
Pregnancy	+ mild dietary deficiency:	oral cyanocobalamin 1 mg daily
pregnancy	+ malabsorption / pernicious anaemia / severe symptoms:	hydroxocobalamin 1 mg IM Usual single IM dose: 1 mg

Important rules

Point	Practical meaning
Do not give folate alone if B12 deficiency is possible	Folate can correct the anaemia while neurological injury continues.
Correct folate and iron deficiency as well	Mixed deficiency can blunt the haematologic response; treatment can also unmask folate deficiency and iron deficiency.
Usual routine IM dose at one time	1 mg (1000 micrograms) IM per injection is the standard routine dose for deficiency treatment.
Can you give more than 1 mg at one time?	Not standard for routine deficiency management, and there is no established routine benefit from larger IM doses.

Expected response

Marker / symptom	Typical response time
Reticulocyte response / marrow recovery	Starts in 3–5 days
Haemoglobin / macrocytic anaemia	Usually improves over 4–8 weeks
Neurological symptoms	Often improve over 6–12 weeks, but recovery may be incomplete if treatment is delayed

Nitrous oxide

Nitrous oxide (“laughing gas,” “nangs”) oxidises and inactivates vitamin B12.
This causes functional B12 deficiency: the vitamin may still be present in blood, but it is not usable by the body
Inactive B12 cannot do its normal jobs:
- Homocysteine → methionine is impaired
- myelin maintenance is disrupted
- this can cause demyelination in the peripheral and central nervous system.
Symptoms
- Patients can develop:
  - numbness or tingling
  - unsteady gait
  - weakness
  - sensory loss
  - sometimes cognitive or mood symptomst
With nitrous oxide exposure:
- total B12 can be normal
- active B12 can also be normal
- so the better tests are homocysteine and/or methylmalonic acid (MMA), because they detect the functional deficiency